



non-coding RNA



Article

Role of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure




Verena Gisa, Md Rezaul Islam, Dawid Lbik, Raoul Maximilian Hofmann, Tonatiuh Pena, Dennis Manfred Krüger, Susanne Burkhardt, Anna-Lena Schütz, Farahnaz Sananbenesi, Karl Toischer et al.



<https://doi.org/10.3390/ncrna11030045>

Article

Role of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure

Verena Gisa ^{1,2} , Md Rezaul Islam ^{1,2}, Dawid Lbik ² , Raoul Maximilian Hofmann ², Tonatiuh Pena ¹, Dennis Manfred Krüger ¹, Susanne Burkhardt ¹, Anna-Lena Schütz ³, Farahnaz Sananbenesi ³, Karl Toischer ^{2,4,5,*} and Andre Fischer ^{1,4,5,6,*} 

- ¹ Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Von Siebold Street 3A, 37075 Goettingen, Germany
 - ² Clinic of Cardiology and Pneumology, Georg-August-University, Robert-Koch Street 38, 37075 Goettingen, Germany
 - ³ Research Group for Genome Dynamics in Brain Diseases, German Center for Neurodegenerative Diseases, Von Siebold Street 3A, 37075 Göttingen, Germany
 - ⁴ Cluster of Excellence “Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells” (MBExC), Von Siebold Street 3A, 37077 Göttingen, Germany
 - ⁵ DZKH (German Center for Cardiovascular Diseases), Robert Koch Street 40, 37075 Göttingen, Germany
 - ⁶ Clinic of Psychiatry and Psychotherapy, University Medical Center, Von Siebold Street 5, 37075 Goettingen, Germany
- * Correspondence: ktoischer@med.uni-goettingen.de (K.T.); andre.fischer@dzne.de (A.F.); Tel.: +49-551-3961211 (A.F.)

Abstract: Background: Heart failure (HF) is associated with an increased risk of cognitive impairment and hippocampal dysfunction, yet the underlying molecular mechanisms remain poorly understood. This study aims to investigate the role of microRNA (miRNA) networks in hippocampus-dependent memory recovery in a mouse model of HF. **Methods:** CaMKIIδC transgenic (TG) mice, a model for HF, were used to assess hippocampal function at 3 and 6 months of age. Memory performance was evaluated using hippocampus-dependent behavioral tasks. Small RNA sequencing was performed to analyze hippocampal miRNA expression profiles across both time points. Bioinformatic analyses identified miRNAs that potentially regulate genes previously implicated in HF-induced cognitive impairment. **Results:** We have previously shown that at 3 months of age, CaMKIIδC TG mice exhibited significant memory deficits associated with dysregulated hippocampal gene expression. In this study, we showed that these impairments, memory impairment and hippocampal gene expression, were no longer detectable at 6 months, despite persistent cardiac dysfunction. However, small RNA sequencing revealed a dynamic shift in hippocampal miRNA expression, identifying 27 miRNAs as “compensatory miRs” that targeted 73% of the transcripts dysregulated at 3 months but reinstated by 6 months. Notably, miR-181a-5p emerged as a central regulatory hub, with its downregulation coinciding with restored memory function. **Conclusions:** These findings suggest that miRNA networks contribute to the restoration of hippocampal function in HF despite continued cardiac pathology and provide an important compensatory mechanism towards memory impairment. A better understanding of these compensatory miRNA mechanisms may provide novel therapeutic targets for managing HF-related cognitive dysfunction.



Academic Editor: Aristeidis G. Telonis

Received: 4 February 2025

Revised: 22 April 2025

Accepted: 5 June 2025

Published: 12 June 2025

Citation: Gisa, V.; Islam, M.R.; Lbik, D.; Hofmann, R.M.; Pena, T.; Krüger, D.M.; Burkhardt, S.; Schütz, A.-L.; Sananbenesi, F.; Toischer, K.; et al. Role of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure. *Non-Coding RNA* **2025**, *11*, 45. <https://doi.org/10.3390/ncrna11030045>

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: heart failure; cognitive impairment; hippocampal function; MicroRNA; transcriptional homeostasis; memory recovery; Alzheimer

1. Introduction

Heart failure (HF) is a leading cause of morbidity and mortality worldwide, affecting millions of people across all age groups [1]. It is a chronic and progressive condition characterized by the inability of the heart to pump blood effectively, leading to systemic effects that extend far beyond the cardiovascular system. Importantly, HF has emerged as a significant risk factor for cognitive decline and neurodegenerative diseases, including Alzheimer's disease (AD) [2].

Patients with HF are at increased risk of developing hippocampal dysfunction, resulting in deficits in learning and memory processes [3]. However, the molecular mechanisms underlying this relationship remain poorly understood. Several studies reported that heart failure leads to altered gene expression patterns in the brain, and other organs [4–6]. In a previous study, we established a strong correlation between cardiac dysfunction and cognitive impairment in a mouse model of HF driven by CaMKII δ C overexpression [6]. Specifically, 3-month-old CaMKII δ C transgenic (TG) mice exhibited significant impairments in hippocampus-dependent memory formation, accompanied by extensive transcriptional dysregulation in hippocampal tissues.

In this study, we analyzed the CaMKII δ C mouse model for HF at 6 months of age and made a surprising observation: memory deficits were no longer apparent, despite the persistence of severe cardiac dysfunction. This raises the intriguing possibility of a compensatory mechanism that restores hippocampal function and homeostasis. At the molecular level, microRNAs (miRNAs) have been established as key regulators of transcriptional and post-transcriptional homeostasis. miRNAs are small, non-coding RNAs that act as fine-tuners of gene expression by binding to complementary mRNA sequences, leading to mRNA degradation or translational repression [7,8]. By buffering fluctuations in gene expression, miRNAs ensure cellular stability and play critical roles in neuronal plasticity, memory formation, and stress responses [9,10]. Given their ability to coordinate the expression of multiple target genes, miRNAs are well-suited to mediate compensatory mechanisms in disease conditions.

Here, we identify a compensatory hippocampal miRNA signature that restores transcriptional homeostasis and may contribute to the rescue of memory deficits in HF. These findings provide new insights into the molecular mechanisms underlying brain resilience and suggest that targeting specific miRNAs may represent a novel therapeutic approach to treating cognitive decline in HF patients.

2. Results

2.1. Six-Month-Old CamKII δ C Mice Exhibit No Memory Impairments Despite Heart Failure

We first confirmed that 6-month-old CamKII δ C mice exhibit significant cardiac dysfunction, as previously reported. Compared to control mice, CamKII δ C mice showed reduced ejection fraction (Figure 1A), cardiac output (Figure 1B), and cardiac index (Figure 1C). Additionally, the heart/body weight ratio (Figure 1D), left ventricle (LV)/body weight ratio (Figure 1E), and lung/body weight ratio (Figure 1F) were significantly increased, indicating heart failure. Body weight remained unchanged between groups (Figure 1G). These data are in agreement with previous studies [11].

Despite this cardiac dysfunction, hippocampus-dependent learning and memory were not impaired in 6-month-old CamKII δ C mice, as assessed using the Barnes maze test. Escape latency decreased similarly in CamKII δ C and control mice over 7 training days (Figure 2A). On day 8, both groups spent comparable time at the target hole (Figure 2B) and within the target quadrant (Figure 2C,D), indicating intact memory.




Figure 1. Heart Failure in 6 months CamKII δ c TG mice. (A) Significantly decreased ejection fraction (B), cardiac output, and cardiac index (C) in CamKII δ c TG mice ($n = 12$) compared to control mice ($n = 16$). (D) Weight ratios of heart to body, (E) left ventricle to body, and (F) lung to body are increased in CamKII δ c TG ($n = 12$) compared to control ($n = 16$). (G) No significant difference in speed, path traveled, and time spent in the middle region in the open field test between CamKII δ c TG ($n = 11$) and control ($n = 15$) mice. There were no sex-specific differences detected except for the cardiac output in the WT group ($p = 0.04$) and overall body weight (WT: $p < 0.00001$; TG $p < 0.00001$). Unpaired t-test, two-tailed; *** $p < 0.001$, **** $p < 0.0001$; Error bars indicate SEM.




Figure 2. Behavioral analysis of 6-month-old CamKII δ c TG mice. (A) Escape latency during training sessions of the Barnes maze test is not affected in 6 old CamKII δ c TG ($n = 11$) and control mice ($n = 15$; two-way ANOVA $p = 0.97$). (B) Time spent at the target hole during the memory test vs. time spent at other holes is not different in 6-month-old CamKII δ c TG ($n = 11$) when compared to control mice ($n = 15$). (C) Time spent in the target quadrant during the memory test in fCamKII δ c TG ($n = 11$) and control mice ($n = 15$) during the memory test. (D) Representative images showing the path of mice during the memory test. (E) Distance traveled in the open field in CamKII δ c ($n = 11$) and control mice ($n = 15$). (F) Speed during the open field test. (G) Time spent in the center area of the open field is similar in CamKII δ c TG and control mice. (H) Representative images showing the performance during the open field test. There were no sex-specific differences detected. Unpaired t-test, two-tailed; Error bars indicate SEM.

To exclude the confounding effects of anxiety or exploratory behavior, we performed an open field test. No significant differences were observed in total distance traveled (Figure 2E), travel speed (Figure 2F), or time spent in the center area (Figure 2G,H), confirming normal exploratory behavior and baseline anxiety.

These results were unexpected, as 3-month-old CamKII δ C mice showed both cardiac dysfunction and impaired memory function [6]. This suggests that a compensatory mechanism may restore hippocampal function in 6-month-old mice.

2.2. Hippocampal Gene Expression Reveals a Potential Compensatory Mechanism

We previously reported that memory impairment in 3-month-old CamKII δ C mice was correlated with significant changes in hippocampal gene expression [6]. To better understand the absence of memory impairment in 6-month-old CamKII δ C mice, we compared hippocampal gene expression in CamKII δ C and control mice at both 3 and 6 months of age. Small and total RNA sequencing (RNA-seq) datasets had been generated previously [6], but the data from the 6-month-old mice had not yet been analyzed. Therefore, we re-analyzed all datasets together.

We compared hippocampal gene expression between 3- and 6-month-old CamKII δ C TG mice and controls. At 3 months, we identified 689 differentially expressed genes (DEGs; 122 up-regulated and 567 down-regulated) in CamKII δ C TG mice ($FDR < 0.05$, $\log_2FC > 0.1$) when compared to the control group. Using a stricter cutoff ($\log_2FC > 0.26$), 246 down-regulated and 52 up-regulated genes were detected (Figure 3A; Supplemental Table S1). As described before, Gene-Ontology (GO)-term analysis revealed that the down-regulated genes were enriched for processes linked to memory function, such as “synaptic transmission” and pathways such as “long-term potentiation” (Supplemental Table S2). In contrast, only 11 DEGs were detected at 6 months ($FDR < 0.05$, $\log_2FC > 0.1$), with just 4 genes meeting the stricter cutoff (Figure 3A). This indicates that hippocampal transcriptional dysregulation observed at 3 months is largely resolved by 6 months (Figures 3B and S1), potentially explaining the restored memory function.

To better understand the potential compensatory gene-expression response occurring between 3 and 6 months of age, we directly compared these two time points using differential expression analysis in both wild-type control and CamKII δ C mice. In wild-type control mice, we identified 223 differentially expressed genes between 3 and 6 months of age (Figure 3C,D; Supplemental Table S1). In contrast, the same comparison in CamKII δ C TG mice revealed 935 differentially expressed genes (Figure 3C,E; Supplemental Table S1).

These results indicate that only minor changes in hippocampal gene expression occur in wild-type control mice over this time period, whereas CamKII δ C TG mice exhibit substantial transcriptional changes. This supports the hypothesis that a compensatory mechanism in CamKII δ C TG mice drives differential gene expression during aging, ultimately reinstating physiological gene-expression levels. As expected, no such process is observed in wild-type control mice.

2.3. A Compensatory miRNA Network May Regulate Gene Expression Recovery

MicroRNAs are known to regulate gene expression at the systems level, with one miRNA being able to control multiple transcripts within a signaling pathway [12]. Thus, miRNAs are recognized as important regulators of cellular homeostasis [13]. By fine-tuning mRNA and protein levels, miRNAs can buffer against fluctuations in gene expression, ensuring stability within cellular networks. Therefore, we hypothesized that altered miRNA expression could mediate the observed compensatory gene-expression response, at least in part.




Figure 3. Gene expression changes in 3 and 6-month-old CamKIIδC TG mice. (A) Bar chart showing the number of differentially expressed genes comparing wild-type control to CamKIIδC TG mice (FDR < 0.05) at either 3 or 6 months of age. (log₂FC was either < 0.1 or < 0.26). (B) Heatmap showing deregulated genes in 3-month-old mice in WT (*n* = 5) and CamKIIδC TG (*n* = 6) and the “rescued” gene expression in 6-month-old CamKIIδC TG mice (*n* = 11), comparable to 6-month-old WT mice (*n* = 15). (C) Bar chart showing the number of differentially expressed genes when 3 vs. 6 months old wild type control (WT) or 3 vs. 6 months old CamKIIδC TG mice (TG) were compared (FDR < 0.05; log₂FC < 0.26). (D) Volcano plot showing the differentially expressed transcripts when comparing 3 vs. 6 months old wild-type control mice. (E) Volcano plot showing the differentially expressed transcripts when comparing 3 vs. 6 months old CamKIIδC TG mice. In (D,E), the horizontal dotted line indicates the significance threshold for the $-\log_{10} P$ -value ($p < 0.05$), while the vertical dotted lines indicate the significance thresholds for the log₂ fold change (± 0.26).

To test this hypothesis, we subjected RNA isolated from the hippocampus of 3- and 6-month-old wild-type control and CamKIIδC TG mice to small RNA sequencing. We observed only minor changes in miRNA expression in 3-month-old mice comparing wild-type control mice and CamKIIδC TG mice, and no changes in miRNA expression in 6-month-old mice (Figure S2). Differential expression analysis revealed that 26 miRNAs were significantly altered (FDR < 0.05, log₂FC > 0.26) in wild-type control mice, with 5 miRNAs downregulated and 21 miRNAs upregulated when comparing the tissue from mice at 3 and 6 months of age (Figure 4A; Supplemental Table S3). In contrast, analysis of CamKIIδC mice revealed 221 miRNAs with significantly altered expression profiles between 3 and 6 months, of which 124 miRNAs were upregulated and 97 miRNAs were

downregulated (Figure 4B; Supplemental Table S3). These results indicate that hippocampal miRNA levels exhibit only minor changes during this time period in wild-type control mice. However, in CamKII δ C mice, substantial changes in miRNA expression occur between 3 and 6 months of age.




Figure 4. Changes in miRNA expression in wild-type control and CamKII δ C TG mice between 3 and 6 months of age. **(A)** Volcano plot showing differentially expressed miRNAs when comparing 3 vs. 6 months old wild type control mice ($n = 5$, $n = 15$, respectively). **(B)** Volcano plot showing differentially expressed miRNAs when comparing 3 vs. 6 months old CamKII δ C TG mice ($n = 6$, $n = 16$, respectively). FDR < 0.05, log₂ FC < 0.26. In A and B the horizontal dotted line indicates the significance threshold for the $-\log_{10} P$ -value ($p < 0.05$), while the vertical dotted lines indicate the significance thresholds for the log₂ fold change (± 0.26).

Next, we tested the hypothesis that miRNAs with altered expression between 3- and 6-month-old CamKII δ C TG mice may target mRNA transcripts that were downregulated in 3-month-old CamKII δ C mice relative to wild-type controls. Since most of the deregulated mRNA transcripts in 3-month-old CamKII δ C TG mice were decreased compared to controls, we focused on this subset of genes. Specifically, we aimed to identify miRNAs that were significantly downregulated between 3 and 6 months in CamKII δ C mice and determine how many of these miRNAs target the downregulated mRNA transcripts that exhibit reinstated expression levels at 6 months (Figure 5A). For this approach, we defined deregulated genes as reinstated if their expression increased by more than 50%, corresponding to a difference in the normalized fold change greater than 1.5 (Supplemental Table S4). This criterion was met by 43% of the deregulated genes. Next, we examined whether any miRNAs significantly downregulated between 3- and 6-month-old CamKII δ C mice target these reinstated transcripts (Supplemental Table S5). Notably, 73% ($n = 94$) of the reinstated genes were targets of these compensatory miRNAs, a group we referred to as “rescued transcripts” (Figure 5B; Supplemental Table S6). Further analysis revealed that the rescued transcripts were mainly regulated by 27 miRNAs, which we termed “compensatory miRs” (Figure 5C). Among the miRNAs with the most targets was miR-181a-5p, a miRNA previously implicated in neuronal plasticity and memory formation [14] (Figure 5C). Other members of the miR-181 family, including miR-181b-5p and miR-181d-5p, were also part of the compensatory miRs. Additionally, the majority of miRNAs from the let-7 family (let-7c-5p, let-7i-5p, let-7a-5p, let-7g-5p, let-7e-5p, let-7d-5p, and miR-98-5p) were identified among the 27 compensatory miRs. Similarly, two members of the miR-29 family (miR-29b-3p and miR-29c-3p), both members of the miR-92 family (miR-92a-3p and miR-92b-3p), and three members of the miR-23/27/24 cluster (miR-27b-3p, miR-23a-3p, and miR-23b-3p) were included. Other notable compensatory miRNAs included miR-1a-3p, miR-667-5p, miR-136-5p, miR-125b-5p, and miR-153-3p (Figure 5C). Next, we performed a GO term

analysis of the reinstated genes that were targets of the compensatory miRs. Interestingly, genes that were upregulated from 3 to 6 months in CamKIIδC mice were linked to processes related to RNA metabolism and mRNA expression (Figure 5D; Supplemental Table S7), which aligns with the notion that the hippocampus engages the compensatory miR network to reinstate physiological gene expression. To gain deeper insights into the functional role of these compensatory miRNAs, we also constructed a transcriptional interaction network based on the 27 miRNAs and 77 rescued genes upregulated in 6-month-old CamKIIδC mice compared to 3-month-old (Figure 5E). This network revealed that the 27 compensatory miRNAs synergistically regulate the expression of rescued transcripts and identified miR-181a-5p as a hub miRNA orchestrating the compensatory response.




Figure 5. A miR RNA network that may act as a compensatory response in heart failure-mediated memory impairment. (A) Schematic illustration of the working hypothesis. (B) Bar graph showing

the percentage of “rescued transcripts” targeted by the “compensatory miRNAs”. (C) Bar chart showing the 27 “compensatory miRNAs” (miRs with ≥ 5 targets) and the number of “rescued transcripts” targeted by each miRNA (blue bars). As a control (black bars), the number of mRNA transcripts upregulated in 3-month-old TG mice is shown. (D) Dot plot showing GO term analysis of the “rescued transcripts” upregulated from 3 to 6 months in CaMKII δ C TG mice. (E) Gene interaction network illustrating the 27 “compensatory miRNAs” (violet; circle size corresponds to the number of target genes regulated by each miRNA) and their relationship with the “rescued transcripts” (blue). This network accounts for 56% of the rescued transcripts.

3. Discussion

In this study, we investigated the molecular mechanisms linking HF to cognitive impairment. Using CaMKII δ C TG mice, we previously demonstrated significant memory impairment at 3 months of age, accompanied by extensive dysregulation of hippocampal gene expression [6]. These data are consistent with epidemiological studies showing that cardiac disease increases the risk of age-associated memory impairment [15–17]. Surprisingly, by 6 months of age, memory deficits were no longer detectable in CaMKII δ C TG mice, suggesting the activation of compensatory mechanisms that restore hippocampal function and transcriptional homeostasis. Therefore, we studied the underlying mechanisms that could help to explain the recovery of hippocampus-dependent memory function in this mouse model of HF, despite the persistence of cardiac dysfunction.

We observed that while hippocampal gene expression was deregulated in 3-month-old CaMKII δ C TG mice, no such differences were detected at 6 months of age. However, molecular changes were not entirely absent in the hippocampus of 6-month-old CaMKII δ C TG mice, as miRNAs exhibited altered expression levels at this time point, suggesting a potential role for a compensatory miRNA network in driving recovery. Specifically, small RNA sequencing revealed significant changes in miRNA expression between 3 and 6 months in CaMKII δ C TG mice, whereas only minor changes were observed in age-matched wild-type controls.

By focusing on mRNA transcripts downregulated at 3 months—which represent the majority of deregulated genes—we found that 43% of these genes exhibited near-complete reinstatement of expression levels at 6 months, suggesting partial recovery of transcriptional activity. Notably, 27 miRNAs, which we termed “compensatory miRs”, were downregulated between 3 and 6 months and targeted 73% of these reinstated transcripts, indicating a critical role for these miRNAs in rescuing gene expression.

Compensatory miRNA responses have been described in various disease contexts, such as responses to cellular stressors like hypoxia and oxidative damage [18–22]. Our current findings extend this concept to HF-induced memory impairment. Among the identified 27 miRNAs, miR-181a-5p emerged as a central hub miRNA within the compensatory network. miR-181a-5p was decreased in the hippocampus of 6-month-old CaMKII δ C TG mice, consistent with previous findings showing that elevated levels of miR-181a-5p are associated with impaired neuronal plasticity, synaptic function, and memory formation [14,23,24]. In turn, inhibition of miR-181a-5p was shown to reinstate memory formation in a mouse model of AD, and its downregulation was linked to improved neuronal integrity in a calorie restriction model that ameliorated age-associated memory impairment in mice [25]. Furthermore, elevated levels of miR-181a-5p were implicated in cell death after cerebral ischemia, while reduced levels were associated with neuronal survival [26–28], supporting the notion that lowering miR-181a-5p levels in disease contexts can improve memory function. These data strongly suggest that its downregulation in CaMKII δ C TG mice between 3 and 6 months likely contributes to the reinstatement of learning ability. Interestingly, additional members of the miR-181 family, including miR-181b-5p and miR-181d-5p, were

also part of this network, suggesting a coordinated role for the miR-181 family in mediating the compensatory response.

Notably, other miRs of the identified “compensatory miR” network represented almost entire miRNA families. For example, we identified several other miRNA families, including the let-7 family and the miR-29 family, which targeted the reinstated transcripts. These miRNAs have been associated with neuroprotection and synaptic remodeling, further supporting their role in restoring hippocampal function [29,30]. Moreover, members of the miR-92 [31], miR-29 [32,33], and miR23/27/24 clusters [34–36], which were part of the “compensatory miR” network, have documented roles in neuronal function and learning behavior. The same is true for miR-1a-3p [37], miR-136-5p [38], miR-125b-5p [39,40], and miR-153-3p [41]. Collectively, these findings highlight the synergistic action of multiple miRNAs in regulating hippocampal gene expression to compensate for early transcriptional deficits.

miRNAs are also discussed as potential biomarkers for cognitive function and neurodegenerative diseases [14,42], though data in this area are sometimes conflicting. For instance, some studies reported that certain miRNAs (e.g., miR-146a) are upregulated in AD patients [14,24], while others found them to be downregulated [43]. If such miRNAs are part of a compensatory response, as indicated by our data, longitudinal measurements of miRNA expression will be crucial for resolving these discrepancies.

Our study has several limitations that warrant consideration and should be addressed in future research. First, while our findings identify a compensatory miRNA network that potentially mediates the restoration of hippocampal function in HF, the specific mechanisms regulating these miRNAs remain unclear. The observation that most compensatory miRs belong to miRNA families acting on similar pathways suggests a concerted action, tightly linking mRNA transcript levels to miRNA regulation. Such mechanisms are well-documented in developmental processes, where miRNAs regulate mRNA levels through feed-forward and feedback loops to stabilize developmental pathways [44]. Nevertheless, our data only provides a model and future research should explore how specific transcription factors or epigenetic processes, such as DNA methylation or histone modifications, contribute to the regulation of this compensatory miRNA network.

While this study focused on hippocampal miRNA and gene expression, HF is a systemic condition likely affecting other brain regions critical for cognitive function. Future research should investigate whether similar compensatory mechanisms operate in other brain areas. Moreover, although we used a well-characterized mouse model of HF, validating these findings in additional models of HF will be important for generalizability. Furthermore, while this study primarily explored transcriptional and miRNA landscapes, other regulatory mechanisms, such as protein–protein interactions and metabolomic changes, may also contribute to the observed recovery of memory function. Employing multi-omics approaches could provide a more comprehensive understanding of the compensatory response. It would also be important to compare the mechanisms underlying the recovery of memory function in this study to those involved in other interventions. For example, aerobic exercise can improve cognitive function in heart failure patients, especially in those who already show cognitive impairment [45]. At the same time, there is evidence that the beneficial effect of exercise on cognitive function is—at least in part—mediated via adaptive changes in miRNA expression [46,47].

Finally, the long-term sustainability of the observed compensatory mechanisms remains uncertain. While hippocampal function appears restored at 6 months, compensatory mechanisms may eventually fail, leading to late-onset cognitive decline. The unexpected observation that 3-month-old CaMKII δ C TG mice displayed memory impairment, which was no longer evident at 6 months, underscores the need for longitudinal studies. Examining

ing CaMKII δ C TG mice at later time points and expanding such analyses to other models of age-associated cognitive decline will be essential.

In conclusion, while our findings provide significant insights into the role of miRNA networks in restoring cognitive function in the context of HF, addressing these remaining questions through future research will refine our understanding and help identify novel therapeutic targets for managing heart failure-associated cognitive dysfunction.

4. Materials and Methods

4.1. Animals and Tissue Preparation

For animal experiments, mice with a genetic background of C57Bl/6J were used. CamkII δ c transgenic and wild-type littermates were housed in standard cages on a 12 h/12 h light/dark cycle with food and water ad libitum. Three- and Six-month-old mice were analyzed for the experiments. Male and female mice were used in the experiments. Following cervical dislocation, the hippocampal sub-region CA1 was isolated. Hearts were dissected by a cut above the base of the aorta and perfused with 0.9% sodium chloride solution until blood-free. Tissues were snap-frozen in liquid nitrogen after collection and stored at -80°C . In addition, the lung was extracted, and its weight was determined.

4.2. Echocardiography

Heart function and dimensions were assessed via echocardiography using a Vevo 2100 imaging platform equipped with a MS-400 30 MHz transducer (Visualsonics, Toronto, ON, Canada). The animals were anesthetized with isoflurane (1–2%), and M-mode sequences of the beating heart were recorded in both the short axis and long axis. These images were utilized to determine left ventricular end-diastolic and end-systolic volumes (calculated as $\text{area} \times \text{length} \times 5/6$). These parameters enabled the calculation of the ejection fraction, serving as an indicator of left ventricular heart function. The investigator conducting the analysis was blinded to the genotype, gender, and age of the animals.

4.3. Open Field Test and Barnes Maze Experiment

The open field test was conducted following the methodology established in a previous study [48]. In this procedure, mice were gently positioned in the center quadrant of the open field arena and given 5 min to explore their surroundings. The travel trajectories of the mice were recorded using VideoMot software version 2 (TSE-Systems, Berlin, Germany). The Barnes Maze experiment was conducted following the protocol described previously [6]. The experimenters were blind to the genotypes.

4.4. RNA Isolation and Sequencing

RNA isolation was performed using RNA Clean and Concentrator kit (Zymo, Irvine, CA, USA) according to the manufacturer's protocol. RNA concentration was measured with NanoDrop, and quality was evaluated using the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Library preparation was performed with a total of 300 ng of RNA input. For mRNA sequencing, cDNA libraries were prepared according to Illumina TruSeq, and 50 bp sequencing reads were run in HiSeq 2000. For small RNA sequencing cDNA library and sequencing have been performed according to the manufacturer's protocol (NEBNext Small RNA library prep set for Illumina), and sequencing was performed on the HiSeq 2000 platform. For totalRNA-seq, we obtained an average sequencing depth of approx. 45 mio. reads from which 88.5% were uniquely mapped. For smallRNA-seq, we obtained an average sequencing depth of approx. 15 mio. reads from which 85.5% were uniquely mapped.

4.5. Bioinformatics Analysis

Sequencing data were processed using a customized in-house software pipeline. Illumina's conversion software bcl2fastq (v2.20.2), was used for adapter trimming and converting the base calls in the per-cycle BCL files to the per-read FASTQ format from raw images. Quality control of raw sequencing data was performed by using FastQC (v0.11.5) [49]. Trimming of 3' adapters for smallRNAseq data was performed using cutadapt (v1.11.0) [50]. The mouse genome version mm10 was used for alignment and annotation of coding and non-coding genes. MicroRNAs were annotated using miRBase [51]. For totalRNAseq, reads were aligned using the STAR aligner (v2.5.2b) [52] and read counts were generated using featureCounts (v1.5.1) [53]. For smallRNAseq, reads were aligned using the map-per.pl script from mirdeep2 (v2.0.1.2) [54] which uses bowtie (v1.1.2) [55] and read counts were generated with the quantifier.pl script from mirdeep2. All read counts were normalized according to library size to transcripts per million (TPM). Differential expression analysis was performed with the DESeq2 (v1.26.0) R (v3.6.3) package [56], here unwanted variance was removed using RUVSeq (v1.20.0) [57]. Gene Ontology (GO) enrichment analysis was performed with clusterProfiler (v4.6.0) [58]. Volcano plots were performed with the R package EnhancedVolcano (v1.12.0) [59]. Identification of interactions between miRNAs deregulated from 3 to 6 months in TG mice and genes that were deregulated in 3-month-old mice WT vs. TG were based on pairwise interactions between 221 miRNAs and 298 genes, and any other annotated targets, whose information was collected from six different databases: NPInter [60], RegNetwork [61], Rise [62], STRING Szklarczyk, 2019, TarBase [63], and TransmiR [64]. All interactions classified as weak (if available) were excluded. The Network was built using Cytoscape (v3.7.2) [65] based on selected 27 "compensatory" miRNAs and 94 genes defined as genes with reinstated expression selected from the initial interaction analysis. The list of pairwise interactors was loaded into Cytoscape to build a network. The initial network was truncated to a core network with PathLinker (v1.4.3) [66] using 1000 paths and the input list as source.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ncrna11030045/s1>, Figure S1. Changes in gene expression in 3 and 6 months-old mice between wild type control and CamKII δ C TG mice. A. Volcano Plots showing differentially expressed genes when comparing WT and TG in 3 months-old mice ($n = 5$, $n = 6$, respectively). B. Volcano Plots showing differentially expressed genes when comparing WT and TG in 6 months-old mice ($n = 11$, $n = 15$, respectively). Figure S2. Changes in miRNA expression in 3 and 6 months-old mice between wild type control and CamKII δ C TG mice. A. Volcano Plots showing differentially expressed miRNAs when comparing WT and TG in 3 months-old mice ($n = 5$, $n = 6$, respectively). B. Volcano Plots showing differentially expressed miRNAs when comparing WT and TG in 6 months-old mice ($n = 15$, $n = 16$, respectively). Table S1. List of significantly deregulated genes in CaMKII δ C TG mice. Table S2. Gene-Ontology (GO)-term analysis of deregulated genes in 3-month-old CaMKII δ C. Table S3. List of significantly deregulated miRNAs in CaMKII δ C TG mice. Table S4. List of genes with reinstated expression in 6m TG mice of deregulated genes from 3 months old mice. Table S5. List of significantly deregulated miRNAs in CaMKII δ C TG mice comparing 3 and 6 months and corresponding deregulated target genes in 3 months old CaMKII δ C TG mice. Table S6. List of miRNAs targeting rescued genes from Supplementary Table S7 and corresponding target genes. Table S7. Gene-Ontology (GO)-term analysis of rescued genes targeted by 27 compensatory miRNAs from Supplementary Table S6.

Author Contributions: V.G. analyzed the data and wrote the manuscript. M.R.I. planned the experiments and isolated RNA for sequencing. D.L. performed the analysis of cardiac phenotypes. R.M.H. performed behavioral analysis. T.P. helped with the analysis of RNAseq data. D.M.K. analyzed smallRNAseq data and generated the mRNA-miRNA interaction network. S.B., A.-L.S. and F.S. planned and performed the RNAseq experiment. K.T. and A.F. conceived, planned, and

supervised the experiments and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: AF was supported by the DFG (Deutsche Forschungsgemeinschaft) priority program 1738, SFB1286, and RTG2824; The EU Joint Programme-Neurodegenerative Diseases (JPND)—EPI-3E; Germany’s Excellence Strategy-EXC 2067/1 390729940. F.S. was supported by the GoBIO project miRassay (16LW0055) by the German Federal Ministry of Science and Education. A.F. and K.T. were supported by the DZHK Innovation Cluster Brain and Heart Interfaces and the RTG2824. K.T. was supported by a DFG Heisenberg Professorship stipend. V.G. was supported by the International Max Planck Research School for Genome Science and is an associate student of the RTG2824.

Institutional Review Board Statement: The animal study protocol was approved by the Institutional Review Board of the University Medical Center, Goettingen, Germany, and the responsible Lower Saxony State office (reference number 04-15/2020).

Data Availability Statement: RNA sequencing data are available via the Gene Expression Omnibus (GEO) database, Accession number: GSE288827 (RNAseq) and GSE288826 (smallRNAseq). All the statistical analyses as mentioned in the main text are performed in Prism (version 9.0) or in R. All Bar Plots show Mean + SEM. Gene ontology enrichment analysis was performed using Fisher’s exact test, followed by a Benjamini–Hochberg correction.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Shahim, B.; Kapelios, C.J.; Savarese, G.; Lund, L.H. Global Public Health Burden of Heart Failure: An Updated Review. *Card. Fail. Rev.* **2023**, *9*, e11. [\[CrossRef\]](#) [\[PubMed\]](#)
- Carpenter, A.E.; Jones, T.R.; Lamprecht, M.R.; Clarke, C.; Kang, I.H.; Friman, O.; Guertin, D.A.; Chang, J.H.; Lindquist, R.A.; Moffat, J.; et al. CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. *Genome Biol.* **2006**, *7*, R100. [\[CrossRef\]](#) [\[PubMed\]](#)
- Kumar, R.; Yadav, S.K.; Palomares, J.A.; Park, B.; Joshi, S.H.; Ogren, J.A.; Macey, P.M.; Fonarow, G.C.; Harper, R.M.; Woo, M.A. Reduced regional brain cortical thickness in patients with heart failure. *PLoS ONE* **2015**, *10*, e0126595. [\[CrossRef\]](#) [\[PubMed\]](#)
- Forman, D.E.; Daniels, K.M.; Cahalin, L.P.; Zavin, A.; Allsup, K.; Cao, P.; Santhanam, M.; Joseph, J.; Arena, R.; Lazzari, A.; et al. Analysis of skeletal muscle gene expression patterns and the impact of functional capacity in patients with systolic heart failure. *J. Card. Fail.* **2014**, *20*, 422–430. [\[CrossRef\]](#)
- Rademaker, M.T.; Pilbrow, A.P.; Ellmers, L.J.; Palmer, S.C.; Davidson, T.; Mbikou, P.; Scott, N.J.A.; Permina, E.; Charles, C.J.; Endre, Z.H.; et al. Acute Decompensated Heart Failure and the Kidney: Physiological, Histological and Transcriptomic Responses to Development and Recovery. *J. Am. Heart Assoc.* **2021**, *10*, e021312. [\[CrossRef\]](#)
- Islam, M.R.; Lbik, D.; Sakib, M.S.; Hofmann, M.; Berulava, T.; Jiménez Mausbach, M.; Cha, J.; Goldberg, M.; Vakhtang, E.; Schiffmann, C.; et al. Epigenetic gene expression links heart failure to memory impairment. *EMBO Mol. Med.* **2021**, *13*, Epub ahead of print. [\[CrossRef\]](#)
- Valinezhad Orang, A.; Safaralizadeh, R.; Kazemzadeh-Bavili, M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. *Int. J. Genom.* **2014**, *2014*, 970607. [\[CrossRef\]](#)
- Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* **2010**, *466*, 835–840. [\[CrossRef\]](#)
- Manakov, S.A.; Morton, A.; Enright, A.J.; Grant, S.G. A Neuronal Transcriptome Response Involving Stress Pathways is Buffered by Neuronal microRNAs. *Front. Neurosci.* **2012**, *6*, 156. [\[CrossRef\]](#)
- Daws, S.E.; Jamieson, S.; de Nijs, L.; Jones, M.; Snijders, C.; Klengel, T.; Joseph, N.F.; Krauskopf, J.; Kleinjans, J.; Vinkers, C.H.; et al. MicroRNA regulation of persistent stress-enhanced memory. *Mol. Psychiatry* **2020**, *25*, 965–976. [\[CrossRef\]](#)
- Maier, L.S.; Zhang, T.; Chen, L.; DeSantiago, J.; Brown, J.H.; Bers, D.M. Transgenic CaMKII δ C overexpression uniquely alters cardiac myocyte Ca²⁺ handling: Reduced SR Ca²⁺ load and activated SR Ca²⁺ release. *Circ. Res.* **2003**, *92*, 904–911. [\[CrossRef\]](#) [\[PubMed\]](#)
- Shivdasani, R.A. MicroRNAs: Regulators of gene expression and cell differentiation. *Blood* **2006**, *108*, 3646–3653. [\[CrossRef\]](#)
- van Wijk, N.; Zohar, K.; Linial, M. Challenging Cellular Homeostasis: Spatial and Temporal Regulation of miRNAs. *Int. J. Mol. Sci.* **2022**, *23*, 16152. [\[CrossRef\]](#) [\[PubMed\]](#)

14. Islam, M.R.; Kaurani, L.; Berulava, T.; Heilbronner, U.; Budde, M.; Centeno, T.P.; Elerdashvili, V.; Zafieriou, M.P.; Benito, E.; Sertel, S.M.; et al. A microRNA-signature that correlates with cognition and is a target against cognitive decline. *EMBO Mol. Med.* **2021**; *Online ahead of print*. [[CrossRef](#)] [[PubMed](#)]
15. Farnsworth von Cederwald, B.; Josefsson, M.; Wählin, A.; Nyberg, L.; Karalija, N. Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia. *Neurology* **2022**, *98*, e2013–e2022. [[CrossRef](#)]
16. van Gennip, A.C.E.; van Sloten, T.T.; Fayosse, A.; Sabia, S.; Singh-Manoux, A. Age at cardiovascular disease onset, dementia risk, and the role of lifestyle factors. *Alzheimer's Dement.* **2024**, *20*, 1693–1702. [[CrossRef](#)]
17. Liang, X.; Huang, Y.; Han, X. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis. *Brain Behav.* **2021**, *11*, e02108. [[CrossRef](#)]
18. Blount, G.S.; Coursey, L.; Kocerha, J. MicroRNA Networks in Cognition and Dementia. *Cells* **2022**, *11*, 1882. [[CrossRef](#)]
19. Mendell, J.T.; Olson, E.N. MicroRNAs in stress signaling and human disease. *Cell* **2012**, *148*, 1172–1187. [[CrossRef](#)]
20. Ripa, R.; Dolfi, L.; Terrigno, M.; Pandolfini, L.; Savino, A.; Arcucci, V.; Groth, M.; Terzibasi Tozzini, E.; Baumgart, M.; Cellerino, A. MicroRNA miR-29 controls a compensatory response to limit neuronal iron accumulation during adult life and aging. *BMC Biol.* **2017**, *15*, 9. [[CrossRef](#)]
21. Kolodziej, F.; McDonagh, B.; Burns, N.; Goljanek-Whysall, K. MicroRNAs as the Sentinels of Redox and Hypertrophic Signalling. *Int. J. Mol. Sci.* **2022**, *23*, 14716. [[CrossRef](#)]
22. Rusu-Nastase, E.G.; Lupan, A.M.; Marinescu, C.I.; Neculachi, C.A.; Preda, M.B.; Burlacu, A. MiR-29a Increase in Aging May Function as a Compensatory Mechanism Against Cardiac Fibrosis Through SERPINH1 Downregulation. *Front. Cardiovasc. Med.* **2022**, *8*, 810241. [[CrossRef](#)]
23. Rodriguez-Ortiz, C.J.; Baglietto-Vargas, D.; Martinez-Coria, H.; LaFerla, F.M.; Kitazawa, M. Upregulation of miR-181 decreases c-Fos and SIRT-1 in the hippocampus of 3xTg-AD mice. *J. Alzheimers Dis.* **2014**, *42*, 1229–1238. [[CrossRef](#)] [[PubMed](#)]
24. Ansari, A.; Maffioletti, E.; Milanese, E.; Marizzoni, M.; Frisoni, G.B.; Blin, O.; Richardson, J.C.; Bordet, R.; Forloni, G.; Gennarelli, M.; et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. *Neurobiol. Aging* **2019**, *82*, 102–109. [[CrossRef](#)]
25. Khanna, A.; Muthusamy, S.; Liang, R.; Sarojini, H.; Wang, E. Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice. *Aging* **2011**, *3*, 223–236. [[CrossRef](#)] [[PubMed](#)]
26. Ouyang, Y.B.; Lu, Y.; Yue, S.; Xu, L.J.; Xiong, X.X.; White, R.E.; Sun, X.; Giffard, R.G. miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. *Neurobiol. Dis.* **2012**, *45*, 555–563. [[CrossRef](#)]
27. Moon, J.M.; Xu, L.; Giffard, R.G. Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss. *J. Cereb. Blood Flow. Metab.* **2013**, *33*, 1976–1982. [[CrossRef](#)] [[PubMed](#)]
28. Xu, L.J.; Ouyang, Y.B.; Xiong, X.; Stary, C.M.; Giffard, R.G. Post-stroke treatment with miR-181 antagomir reduces injury and improves long-term behavioral recovery in mice after focal cerebral ischemia. *Exp. Neurol.* **2015**, *26*, 1–7. [[CrossRef](#)]
29. Lehmann, S.K.C.; Park, B.; Derkow, K.; Rosenberger, K.; Baumgart, J.; Trimbuch, T.; Eom, G.; Hinz, M.; Kaul, D.; Habbel, P.; et al. An unconventional role for miRNA: Let-7 activates Toll-like receptor 7 and causes neurodegeneration. *Nat. Neurosci.* **2012**, *15*, 827–835. [[CrossRef](#)]
30. Roshan, R.; Shridhar, S.; Sarangdhar, M.A.; Banik, A.; Chawla, M.; Garg, M.; Singh, V.P.; Pillai, B. Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. *RNA* **2014**, *20*, 1287–1297. [[CrossRef](#)]
31. Vetere, G.; Barbato, C.; Pezzola, S.; Frisone, P.; Aceti, M.; Ciotti, M.; Cogoni, C.; Ammassari-Teule, M.; Ruberti, F. Selective inhibition of miR-92 in hippocampal neurons alters contextual fear memory. *Hippocampus* **2014**, *24*, 1458–1465. [[CrossRef](#)]
32. Ma, R.; Wang, M.; Gao, S.; Zhu, L.; Yu, L.; Hu, D.; Zhu, L.; Huang, W.; Zhang, W.; Deng, J.; et al. miR-29a Promotes the Neurite Outgrowth of Rat Neural Stem Cells by Targeting Extracellular Matrix to Repair Brain Injury. *Stem Cells Dev.* **2020**, *29*, 599–614. [[CrossRef](#)]
33. Swahari, V.; Nakamura, A.; Hollville, E.; Stroud, H.; Simon, J.M.; Ptacek, T.S.; Beck, M.V.; Flowers, C.; Guo, J.; Plestant, C.; et al. MicroRNA-29 is an essential regulator of brain maturation through regulation of CH methylation. *Cell Rep.* **2021**, *35*, 108946. [[CrossRef](#)]
34. Roshan-Milani, S.; Sattari, P.; Ghaderi-Pakdel, F.; Naderi, R. miR-23b/TAB3/NF-κB/p53 axis is involved in hippocampus injury induced by cerebral ischemia-reperfusion in rats: The protective effect of chlorogenic acid. *Biofactors* **2022**, *48*, 908–917. [[CrossRef](#)]
35. Lu, J.; Zhou, N.; Yang, P.; Deng, L.; Liu, G. MicroRNA-27a-3p Downregulation Inhibits Inflammatory Response and Hippocampal Neuronal Cell Apoptosis by Upregulating Mitogen-Activated Protein Kinase 4 (MAP2K4) Expression in Epilepsy: In Vivo and In Vitro Studies. *Med. Sci. Monit.* **2019**, *25*, 8499–8508. [[CrossRef](#)]
36. Wang, Z.; Yuan, Y.; Zhang, Z.; Ding, K. Inhibition of miRNA-27b enhances neurogenesis via AMPK activation in a mouse ischemic stroke model. *FEBS Open Bio* **2019**, *9*, 859–869. [[CrossRef](#)]
37. Neumann, E.; Brandenburger, T.; Santana-Varela, S.; Deenen, R.; Köhrer, K.; Bauer, I.; Hermanns, H.; Wood, J.N.; Zhao, J.; Werdehausen, R. MicroRNA-1-associated effects of neuron-specific brain-derived neurotrophic factor gene deletion in dorsal root ganglia. *Mol. Cell Neurosci.* **2016**, *75*, 36–43. [[CrossRef](#)]

38. He, J.; Zhao, J.; Peng, X.; Shi, X.; Zong, S.; Zeng, G. Molecular Mechanism of MiR-136-5p Targeting NF- κ B/A20 in the IL-17-Mediated Inflammatory Response after Spinal Cord Injury. *Cell. Physiol. Biochem.* **2017**, *44*, 1224–1241. [CrossRef]
39. Cui, Y.; Xiao, Z.; Han, J.; Sun, J.; Ding, W.; Zhao, Y.; Chen, B.; Li, X.; Dai, J. MiR-125b orchestrates cell proliferation, differentiation and migration in neural stem/progenitor cells by targeting Nestin. *BMC Neurosci.* **2012**, *13*, 116. [CrossRef] [PubMed]
40. Marcuzzo, S.; Bonanno, S.; Kapetis, D.; Barzago, C.; Cavalcante, P.; D'Alessandro, S.; Mantegazza, R.; Bernasconi, P. Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage. *Mol. Brain* **2015**, *8*, 5. [CrossRef] [PubMed]
41. Qiao, J.; Zhao, J.; Chang, S.; Sun, Q.; Liu, N.; Dong, J.; Chen, Y.; Yang, D.; Ye, D.; Liu, X.; et al. MicroRNA-153 improves the neurogenesis of neural stem cells and enhances the cognitive ability of aged mice through the notch signaling pathway. *Cell Death Differ.* **2020**, *27*, 808–825. [CrossRef] [PubMed]
42. Krüger, D.M.; Pena, T.; Liu, S.; Park, T.; Kaurani, L.; Pradhan, R.; Huang, Y.; Rischer, S.L.; Burkhardt, S.; Schütz, A.; et al. The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. *Alzheimer's Dement.* **2024**; online ahead of print. [CrossRef] [PubMed]
43. Zhang, B.; Wang, A.; Xia, C.; Lin, Q.; Chen, C. A single nucleotide polymorphism in primary-microRNA-146a reduces the expression of mature microRNA-146a in patients with Alzheimer's disease and is associated with the pathogenesis of Alzheimer's disease. *Mol. Med. Rep.* **2015**, *12*, 4037–4042. [CrossRef] [PubMed]
44. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. *Cell* **2009**, *136*, 215–233. [CrossRef]
45. Peng, J.Y.; Chen, Y.H.; Yen, J.H.; Huang, W.M.; Chen, C.N. Effects of Exercise Training on Cognitive Function in Individuals With Heart Failure: A Meta-Analysis. *Phys. Ther.* **2023**, *103*, pzad027. [CrossRef]
46. Goldberg, M.; Islam, R.M.; Kerimoglu, C.; Lacelin, C.; Burkhardt, S.; Krüger, D.M.; Marquardt, T.; Malchow, B.; Schmitt, A.; Falkai, P.; et al. Exercise as a model to identify microRNAs linked to human cognition: A role for microRNA-409 and microRNA-501. *Transl. Psychiatry* **2021**, *11*, 514. [CrossRef]
47. Han, Z.; Zhang, L.; Ma, M.; Keshavarzi, M. Effects of MicroRNAs and Long Non-coding RNAs on Beneficial Action of Exercise on Cognition in Degenerative Diseases: A Review. *Mol. Neurobiol.* **2025**, *62*, 485–500. [CrossRef]
48. Bahari-Javan, S.; Maddalena, A.; Kerimoglu, C.; Wittnam, J.; Held, T.; Bähr, M.; Burkhardt, S.; Delalle, I.; Kügler, S.; Fischer, A.; et al. HDAC1 Regulates Fear Extinction in Mice. *J. Neurosci.* **2012**, *32*, 5062–5073. [CrossRef]
49. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (accessed on 1 June 2025).
50. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. J.* **2011**, *17*, 3. [CrossRef]
51. Griffiths-Jones, S. miRBase: The microRNA sequence database. *Methods Mol. Biol.* **2006**, *342*, 129–138.
52. Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **2013**, *13*, 673–691. [CrossRef]
53. Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **2014**, *30*, 923–930. [CrossRef]
54. Friedländer, M.R.; Mackowiak, S.D.; Li, N.; Chen, W.; Rajewsky, N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. *Nucleic Acids Res.* **2011**, *40*, 37–52. [CrossRef] [PubMed]
55. Langmead, B.; Trapnell, C.; Pop, M.; Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **2009**, *10*, R25. [CrossRef] [PubMed]
56. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **2014**, *15*, 550. [CrossRef] [PubMed]
57. Risso, D.; Ngai, J.; Speed, T.P.; Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. *Nat. Biotechnol.* **2014**, *32*, 896. [CrossRef]
58. Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. *Omics J. Integr. Biol.* **2012**, *16*, 284–286. [CrossRef]
59. Blighe, K.; Rana, S.; Lewis, M. EnhancedVolcano: Publication-Ready Volcano Plots with Enhanced Colouring and Labeling. Available online: <https://github.com/kevinblighe/EnhancedVolcano> (accessed on 1 June 2025).
60. Teng, X.; Chen, X.; Xue, H.; Tang, Y.; Zhang, P.; Kang, Q.; Hao, Y.; Chen, R.; Zhao, Y.; He, S. NPInter v4.0: An integrated database of ncRNA interactions. *Nucleic Acids Res.* **2020**, *48*, 160–165. [CrossRef]
61. Liu, Z.P.; Wu, C.; Miao, H.; Wu, H. RegNetwork: An integrated database of transcriptional and post-transcriptional regulatory networks in human and mouse. *Database J. Biol. Databases Curatio* **2015**, *2015*, bav095. [CrossRef]
62. Gong, J.; Shao, D.; Xu, K.; Lu, Z.; Lu, Z.; Yang, Y.T.; Zhang, Q.C. RISE: A database of RNA interactome from sequencing experiments. *Nucleic Acids Res.* **2018**, *46*, D194–D201. [CrossRef]
63. Karagkouni, D.; Paraskevopoulou, M.D.; Chatzopoulos, S.; Vlachos, I.S.; Tastsoglou, S.; Kanellos, I.; Papadimitriou, D.; Kavakiotis, I.; Maniou, S.; Skoufos, G.; et al. DIANA-TarBase v8: A decade-long collection of experimentally supported miRNA-gene interactions. *Nucleic Acids Res.* **2018**, *46*, D239–D245. [CrossRef] [PubMed]

64. Tong, Z.; Cui, Q.; Wang, J.; Zhou, Y. TransmiR v2.0: An updated transcription factor-microRNA regulation database. *Nucleic Acids Res.* **2019**, *47*, D253–D258. [[CrossRef](#)] [[PubMed](#)]
65. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res.* **2003**, *13*, 2498–2504. [[CrossRef](#)]
66. Gil, D.P.; Law, J.N.; Murali, T.M. The PathLinker app: Connect the dots in protein interaction networks. *F1000Research* **2017**, *6*, 58. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.